Pfizer has significantly bolstered its position in the obesity therapeutics market by acquiring Metsera Inc. for an upfront $4.9 billion with contingent value rights potentially raising the deal to $7.3 billion. Metsera's portfolio includes injectable and oral GLP-1 receptor agonists and other novel candidates aiming to improve dosing convenience and tolerability. The acquisition follows Pfizer’s earlier internal setbacks in obesity drug development. Metsera's lead GLP-1 candidate has met phase II endpoints, and further pivotal trials are planned. Pfizer's CEO Albert Bourla highlighted the strategic fit with the company’s focus on impactful investments in metabolic disease. Market analysts project strong commercial potential for Metsera's drug candidate pipeline.